Cliff Asness’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.3M | Buy |
442,287
+98,098
| +29% | +$4.01M | 0.01% | 1094 |
|
|
2026
Q1 | $11.4M | Buy |
344,189
+208,181
| +153% | +$6.2M | 0.01% | 1276 |
|
|
2025
Q4 | $4.05M | Buy |
136,008
+68,197
| +101% | +$2.23M | ﹤0.01% | 1700 |
|
|
2025
Q3 | $2.45M | Buy |
67,811
+34,462
| +103% | +$1.14M | ﹤0.01% | 1862 |
|
|
2025
Q2 | $1.2M | Sell |
33,349
-1,944
| -6% | -$72.4K | ﹤0.01% | 2087 |
|
|
2025
Q1 | $1.39M | Sell |
35,293
-32,574
| -48% | -$1.1M | ﹤0.01% | 1818 |
|
|
2024
Q4 | $2.04M | Buy |
67,867
+8,431
| +14% | +$242K | ﹤0.01% | 1525 |
|
|
2024
Q3 | $1.39M | Buy |
59,436
+21,411
| +56% | +$468K | ﹤0.01% | 1682 |
|
|
2024
Q2 | $676K | Sell |
38,025
-6,339
| -14% | -$101K | ﹤0.01% | 1923 |
|
|
2024
Q1 | $675K | Buy |
44,364
+26,477
| +148% | +$422K | ﹤0.01% | 1842 |
|
|
2023
Q4 | $306K | Sell |
17,887
-41,968
| -70% | -$488K | ﹤0.01% | 2058 |
|
|
2023
Q3 | $500K | Sell |
59,855
-3,783
| -6% | -$52.7K | ﹤0.01% | 1843 |
|
|
2023
Q2 | $1.58M | Buy |
63,638
+20,261
| +47% | +$523K | ﹤0.01% | 1366 |
|
|
2023
Q1 | $652K | Buy |
+43,377
| New | +$659K | ﹤0.01% | 1687 |
|
|
2022
Q2 | – | Sell |
-34,081
| Closed | -$324K | – | 2296 |
|
|
2022
Q1 | $324K | Hold |
34,081
| – | – | ﹤0.01% | 1947 |
|
|
2021
Q4 | $648K | Sell |
34,081
-16,354
| -32% | -$425K | ﹤0.01% | 1743 |
|
|
2021
Q3 | $1.68M | Sell |
50,435
-12,173
| -19% | -$377K | ﹤0.01% | 1248 |
|
|
2021
Q2 | $2.43M | Hold |
62,608
| – | – | ﹤0.01% | 1123 |
|
|
2021
Q1 | $3.02M | Sell |
62,608
-9,148
| -13% | -$440K | ﹤0.01% | 984 |
|
|
2020
Q4 | $3.73M | Sell |
71,756
-5,012
| -7% | -$169K | 0.01% | 884 |
|
|
2020
Q3 | $2.05M | Buy |
76,768
+7,898
| +11% | +$182K | ﹤0.01% | 1095 |
|
|
2020
Q2 | $1.34M | Buy |
68,870
+24,075
| +54% | +$388K | ﹤0.01% | 1346 |
|
|
2020
Q1 | $441K | Buy |
44,795
+8,624
| +24% | +$109K | ﹤0.01% | 1626 |
|
|
2019
Q4 | $401K | Buy |
+36,171
| New | +$275K | ﹤0.01% | 1824 |
|
|
2018
Q4 | – | Sell |
-16,948
| Closed | -$95K | – | 2270 |
|
|
2018
Q3 | $95K | Sell |
16,948
-18,836
| -53% | -$215K | ﹤0.01% | 2244 |
|
|
2018
Q2 | $471K | Sell |
35,784
-11,483
| -24% | -$158K | ﹤0.01% | 1995 |
|
|
2018
Q1 | $671K | Buy |
47,267
+730
| +2% | +$9.33K | ﹤0.01% | 1819 |
|
|
2017
Q4 | $382K | Hold |
46,537
| – | – | ﹤0.01% | 2001 |
|
|
2017
Q3 | $551K | Buy |
46,537
+36,263
| +353% | +$413K | ﹤0.01% | 1907 |
|
|
2017
Q2 | $103K | Buy |
+10,274
| New | +$115K | ﹤0.01% | 2173 |
|
|
2015
Q4 | – | Sell |
-53,123
| Closed | -$535K | – | 2307 |
|
|
2015
Q3 | $535K | Sell |
53,123
-9,937
| -16% | -$148K | ﹤0.01% | 1687 |
|
|
2015
Q2 | $1.05M | Buy |
63,060
+13,560
| +27% | +$215K | ﹤0.01% | 1467 |
|
|
2015
Q1 | $766K | Buy |
49,500
+1,100
| +2% | +$16.7K | ﹤0.01% | 1532 |
|
|
2014
Q4 | $767K | Buy |
48,400
+19,500
| +67% | +$254K | ﹤0.01% | 1775 |
|
|
2014
Q3 | $308K | Buy |
28,900
+11,400
| +65% | +$106K | ﹤0.01% | 2164 |
|
|
2014
Q2 | $164K | Sell |
17,500
-25,600
| -59% | -$164K | ﹤0.01% | 2407 |
|
|
2014
Q1 | $297K | Hold |
43,100
| – | – | ﹤0.01% | 2270 |
|
|
2013
Q4 | $168K | Buy |
43,100
+32,900
| +323% | +$133K | ﹤0.01% | 2460 |
|
|
2013
Q3 | $52K | Buy |
+10,200
| New | +$62.4K | ﹤0.01% | 2457 |
|
Other funds holding TGTX
SCM
CAM
Cliff Asness's TGTX Position: Q2 2026 in Review
Cliff Asness increased its TG Therapeutics (TGTX) stake by 29% in Q2 2026, buying an estimated $4.01M and bringing the position to 442,287 shares worth $24.3M. The position accounts for 0.01% of the portfolio, ranked #1094.
Cliff Asness first reported a position in TGTX in Q3 2013 and has held it in 39 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- Cliff Asness held 442,287 shares of TG Therapeutics worth $24.3M as of Q2 2026.
- Cliff Asness bought 98,098 TG Therapeutics shares in Q2 2026, an estimated $4.01M.
- TG Therapeutics made up 0.01% of Cliff Asness's portfolio in Q2 2026, its #1094 holding.
- Cliff Asness first reported a position in TG Therapeutics in Q3 2013 and has held it in 39 quarters since.
- 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.